3 August 2023
NanoCell Therapeutics Inc. Appoints Florence Salmon, PhD to its Scientific Advisory Board

King of Prussia, PA – August 3, 2023 – NanoCell Therapeutics, Inc. (“NanoCell”) today announced the appointment of Dr. Florence G.C. Salmon to its Scientific Advisory Board (“SAB”). Dr. Florence G.C. Salmon joins NanoCell Therapeutics as a member of its SAB and as an Executive Advisor, leveraging her extensive expertise in regulatory affairs and complex biologics manufacturing.

“We eagerly anticipate collaborating with Dr. Florence Salmon, a renowned expert in genetically modified T cells for cancer immunotherapy,” remarked Maurits W. Geerlings, President and CEO of NanoCell Therapeutics. “With Dr. Salmon’s profound understanding of regulatory affairs and complex biologics manufacturing, we’re poised to unlock the full potential of our in vivo gene therapy platform and its associated drug candidates,” added Dr. Geerlings.

Joining NanoCell’s SAB, Dr. Salmon will work alongside esteemed members like Dr. Molly Stevens of Imperial College London, Dr. Dan Peer from Tel Aviv University, Dr. Gianpietro Dotti from the University of North Carolina, Dr. Perry Hackett at the University of Minnesota, and Dr. Marlene Haffner, formerly the Director of the US Food and Drug Administration’s Office of Orphan Drug Products Development. The SAB acts as a strategic guide for NanoCell in its ongoing efforts to develop in vivo gene therapies for cancer and autoimmune diseases.

As a distinguished drug development and regulatory professional, Dr. Salmon possesses unique expertise in spearheading the development and approval of global Cell and Gene Therapies such as Glybera, Kymriah, Zolgensma, and Luxturna. Her vast experience spans non-clinical development, safety, and manufacturing of viral vectors and human adoptive cell therapies. Moreover, her influential role since the early 2000s as a member of EFPIA and BIO working groups on ATMPs and as chair of the EFPIA working group on ATMPs manufacturing and GMP has endowed her with an expansive industry and regulatory network.

On her appointment, Dr. Salmon expressed, “The assembly of thought leaders on NanoCell’s SAB represents a premier team of global authorities in cancer and nanomedicine. I’m honored to collaborate with this caliber of experts and eagerly anticipate contributing to NanoCell’s innovative approach to in vivo gene therapy for the betterment of patients.”


About NanoCell Therapeutics, Inc.

NanoCell Therapeutics is a privately-held biotechnology company with offices in King of Prussia, Pennsylvania, and Utrecht, the Netherlands. Our mission is to revolutionize in-vivo cell engineering through our groundbreaking non-viral, DNA-based gene therapy platform, primarily focusing on oncology and autoimmune diseases. At NanoCell, we’re driving innovation by transforming traditional adoptive cell therapy methods into advanced in-vivo treatments. Our ultimate goal is to simplify the treatment process, increasing patient accessibility, potential clinical benefits, and cost-effective manufacturing. We work both autonomously and in collaboration with partners to make substantial advancements in our targeted disease areas. For more information, please visit our website at http://www.nanocelltx.com.

Investor & Media Contact:
A. Lindman, MBA
+31 (0) 70 3643095

Contact Details

Head Office:

NanoCell Therapeutics Inc.
150 N Radnor Chester Road
Suite A210
Wayne PA  19087
United States

Follow Us